# Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7

> **NCT04777851** · PHASE3 · TERMINATED · sponsor: **Translational Research in Oncology** · enrollment: 45 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Regorafenib in combination with pembrolizumab
- **PROCEDURE:** Loco-regional therapy

## Key facts

- **NCT ID:** NCT04777851
- **Lead sponsor:** Translational Research in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-10-11
- **Primary completion:** 2026-02-26
- **Final completion:** 2026-02-26
- **Target enrollment:** 45 (ACTUAL)
- **Why stopped:** The trial ended earlier than planned due to slow enrolment, which has made it unfeasible to achieve the target sample size within a reasonable timeframe. Consequently, a business decision has been made to discontinue funding for the trial.
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04777851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04777851, "Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04777851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*